KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis & Investment Frameworks
KalVista Pharmaceuticals, Inc. (KALV) stock analysis on Invetso. Review KalVista Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
KalVista Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
KalVista Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $1.44B
- Revenue: $73.62M
- ROE: -1057.44%
- ROIC: -46.81%
- Dividend Yield: N/A
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
KalVista Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes KalVista Pharmaceuticals, Inc. (KALV) across the following frameworks:
- KalVista Pharmaceuticals, Inc. 10Y Growth Potential
- KalVista Pharmaceuticals, Inc. Scenario Analysis
- KalVista Pharmaceuticals, Inc. Risks & Opportunities
- KalVista Pharmaceuticals, Inc. Economic Moat
- KalVista Pharmaceuticals, Inc. Business Model
- KalVista Pharmaceuticals, Inc. Management
- KalVista Pharmaceuticals, Inc. SWOT Analysis
- KalVista Pharmaceuticals, Inc. Porter's 5 Forces
- KalVista Pharmaceuticals, Inc. PESTLE Analysis
- KalVista Pharmaceuticals, Inc. ESG Analysis